Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled BMD003 in Chinese Patients With Cystic Fibrosis
NCT07485543Phase 1Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2026
- Primary completion
- Dec 2026
- Modality
- mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BMD003 in cystic fibrosis (CF), sponsored by Peking Union Medical College Hospital. Primary endpoint: Incidence of adverse events (AE) and serious adverse events (SAE) at 12 months. Started Apr 2026; status: recruiting.
02
Drugs
BMD003
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT07485543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07485543.